A Phase 2 interventional study of Calcipotriol plus hydrocortisone (LEO 80190) in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 35th largest by enrollment, is one of 5 that started in 2008, is one of 9 in phase 2, and was the 16th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 47th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2008, is one of 24 in phase 2, and was the 12th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to monitor the effect of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g on the hypothalamic-pituitary-adrenal axis and on the calcium metabolism in patients with psoriasis vulgaris on the face and on the intertriginous areas
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Calcipotriol plus hydrocortisone (LEO 80190)
Drug pages: Calcipotriene · Hydrocortisone
Once daily application
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
Time frame: At Week 4 (Day 28) and Week 8 (Day 56)
Change in Albumin Corrected Serum Calcium
Baseline was defined as the last assessment performed before study medication application. The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).
Time frame: From baseline to Week 4, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
Time frame: At Week 4 and Week 8
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
Time frame: At Week 4 and Week 8
Serum Cortisol Concentration After 30 Minutes
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.
Time frame: At Week 4 and Week 8
Serum Cortisol Concentration After 60 Minutes
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.
Time frame: At Week 4 and Week 8
Change in Albumin Corrected Serum Calcium
Baseline was defined as the last assessment performed before study medication application.
Time frame: From baseline to Week 2 and Week 6
Albumin Corrected Serum Calcium
The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).
Time frame: At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Albumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range
The table summarizes the shifts in albumin corrected serum calcium versus the normal range. The end of treatment data was defined as the last value recorded for the parameter during the treatment phase of the study (i.e. Week 4, 6, or 8). The normal reference range for the albumin corrected serum calcium was defined as 2.1-2.64 mmol/L (8.4-10.6 mg/L). The value below this level was considered 'low', while the value above this range was considered 'high'.
Time frame: At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face
Controlled disease was defined as the following (P=Plaque thickening, S=Scaling, E=Erythema) Clear (Plaque thickening=no elevation/thickening of normal skin, S=no evidence of scaling, E= none/hyperpigmentation/residual red coloration) or Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) (last value recorded i.e. Week 4, 6, or 8)
Time frame: At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the IGA of the Intertriginous Areas
Controlled disease was defined as the following: Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) or Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) The end of treatment data was defined as the last value recorded for the efficacy measure.
Time frame: At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Overall Disease Severity of the Face According to the IGA
6-category scale based on plaque thickening (P), Scaling (S), Erythema (E). Clear (P=no elevation/thickening of normal skin, S=no evidence of scaling, E=none/hyperpigmentation/residual red coloration) Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) Mild (P=slight but definite elevation, S=fine scales partially/mostly covering lesions, E=light red coloration) Moderate (P=moderate elevation with rounded or sloped edges, S=most lesions at least partially covered, E=definite red coloration) Severe (P =marked elevation typically with hard or sharp edges, S=non-tenacious scale predominates, covering most or all of the lesions, E=very bright red coloration) Very severe (P=very marked elevation typically with hard or sharp edges, S=thick tenacious scale covers most or all of the lesions, E=extreme red coloration, deep red coloration)
Time frame: At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Overall Disease Severity of Intertriginous Areas According to the IGA
The assessment of the disease severity of the intertriginous areas was made using the 6-category scale; clear, almost clear, mild, moderate, severe, very severe. Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) Mild (Infiltration = slight, subtle thickening or infiltration, only marginally increased from normal skin, Erythema = light pink colour) Moderate (Infiltration = palpable thickening or infiltration without elevation, Erythema = definite pink colour) Severe (Infiltration = palpable thickening or infiltration with elevation, Erythema = very bright red coloration) Very severe (Infiltration = marked thickening or infiltration with rounded or sloped edges, Erythema = bright deep red coloration)
Time frame: At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
The treatment phase was divided into two 4-week treatment periods during which the overall treatment duration had to be 28 days or 56 days. The participant was to leave the study if they were clear according to the investigator's global assessment of disease severity (IGA) of the face and of the intertriginous areas at Visit 3 (Day 28).
| Milestone | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Started | 33 |
| Completed | 31 |
| Not completed | 2 |
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| >18 mcg/dL | 29 |
| ≤18 mcg/dL | 1 |
Baseline was defined as the last assessment performed before study medication application. The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).
| mmol/L | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Baseline | 2.215 (2.188 to 2.243) |
| Week 4 (Day 28) | 0.002 (-0.026 to 0.029) |
| Week 8 (Day 56) | -0.045 (-0.083 to -0.007) |
| End of Treatment (last value recorded) | -0.033 (-0.066 to 0.000) |
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| >18 mcg/dL | 29 |
| ≤18 mcg/dL | 1 |
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| >18 mcg/dL | 30 |
| ≤18 mcg/dL | 0 |
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.
| mcg/dL | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Week 4 (Day 28) | 25.29 ± 4.35 |
| Week 8 (Day 56) | 25.93 ± 4.73 |
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.
| mcg/dL | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Week 4 (Day 28) | 28.81 ± 3.48 |
| Week 8 (Day 56) | 28.82 ± 5.30 |
Baseline was defined as the last assessment performed before study medication application.
| mmol/L | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Baseline | 2.215 ± 0.077 |
| Week 2 (Day 14) | 0.018 ± 0.095 |
| Week 6 (Day 42) | -0.013 ± 0.083 |
The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).
| mmol/L | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Week 2 (Day 14) | 2.233 ± 0.079 |
| Week 4 (Day 28) | 2.217 ± 0.074 |
| Week 6 (Day 42) | 2.208 ± 0.096 |
| Week 8 (Day 56) | 2.179 ± 0.085 |
| End of Treatment (last value recorded) | 2.182 ± 0.081 |
The table summarizes the shifts in albumin corrected serum calcium versus the normal range. The end of treatment data was defined as the last value recorded for the parameter during the treatment phase of the study (i.e. Week 4, 6, or 8). The normal reference range for the albumin corrected serum calcium was defined as 2.1-2.64 mmol/L (8.4-10.6 mg/L). The value below this level was considered 'low', while the value above this range was considered 'high'.
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Week 2 (Day 14) — Low | 2 |
| Week 2 (Day 14) — Normal | 30 |
| Week 2 (Day 14) — High | 0 |
| Week 4 (Day 28) — Low | 3 |
| Week 4 (Day 28) — Normal | 30 |
| Week 4 (Day 28) — High | 0 |
| Week 6 (Day 42) — Low | 2 |
| Week 6 (Day 42) — Normal | 26 |
| Week 6 (Day 42) — High | 0 |
| Week 8 (Day 56) — Low | 6 |
| Week 8 (Day 56) — Normal | 21 |
| Week 8 (Day 56) — High | 0 |
| End of Treatment (last value recorded) — Low | 6 |
| End of Treatment (last value recorded) — Normal | 27 |
| End of Treatment (last value recorded) — High | 0 |
Controlled disease was defined as the following (P=Plaque thickening, S=Scaling, E=Erythema) Clear (Plaque thickening=no elevation/thickening of normal skin, S=no evidence of scaling, E= none/hyperpigmentation/residual red coloration) or Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) (last value recorded i.e. Week 4, 6, or 8)
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Week 4 (Day 28) — Controlled | 21 |
| Week 4 (Day 28) — Non-controlled | 12 |
| Week 8 (Day 56) — Controlled | 19 |
| Week 8 (Day 56) — Non-controlled | 9 |
| End of Treatment (last value recorded) — Controlled | 23 |
| End of Treatment (last value recorded) — Non-controlled | 10 |
Controlled disease was defined as the following: Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) or Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) The end of treatment data was defined as the last value recorded for the efficacy measure.
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Week 4 (Day 28) — Controlled | 20 |
| Week 4 (Day 28) — Non-controlled | 13 |
| Week 8 (Day 56) — Controlled | 19 |
| Week 8 (Day 56) — Non-controlled | 9 |
| End of Treatment (last value recorded) — Controlled | 23 |
| End of Treatment (last value recorded) — Non-controlled | 10 |
6-category scale based on plaque thickening (P), Scaling (S), Erythema (E). Clear (P=no elevation/thickening of normal skin, S=no evidence of scaling, E=none/hyperpigmentation/residual red coloration) Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) Mild (P=slight but definite elevation, S=fine scales partially/mostly covering lesions, E=light red coloration) Moderate (P=moderate elevation with rounded or sloped edges, S=most lesions at least partially covered, E=definite red coloration) Severe (P =marked elevation typically with hard or sharp edges, S=non-tenacious scale predominates, covering most or all of the lesions, E=very bright red coloration) Very severe (P=very marked elevation typically with hard or sharp edges, S=thick tenacious scale covers most or all of the lesions, E=extreme red coloration, deep red coloration)
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Baseline — Clear | 0 |
| Baseline — Almost clear | 0 |
| Baseline — Mild | 0 |
| Baseline — Moderate | 27 |
| Baseline — Severe | 6 |
| Baseline — Very severe | 0 |
| Week 2 (Day 14) — Clear | 0 |
| Week 2 (Day 14) — Almost clear | 12 |
| Week 2 (Day 14) — Mild | 15 |
| Week 2 (Day 14) — Moderate | 5 |
| Week 2 (Day 14) — Severe | 1 |
| Week 2 (Day 14) — Very severe | 0 |
| Week 4 (Day 28) — Clear | 5 |
| Week 4 (Day 28) — Almost clear | 16 |
| Week 4 (Day 28) — Mild | 9 |
| Week 4 (Day 28) — Moderate | 2 |
| Week 4 (Day 28) — Severe | 1 |
| Week 4 (Day 28) — Very severe | 0 |
| Week 6 (Day 42) — Clear | 5 |
| Week 6 (Day 42) — Almost clear | 15 |
| Week 6 (Day 42) — Mild | 7 |
| Week 6 (Day 42) — Moderate | 1 |
| Week 6 (Day 42) — Severe | 0 |
| Week 6 (Day 42) — Very severe | 0 |
| Week 8 (Day 56) — Clear | 5 |
| Week 8 (Day 56) — Almost clear | 14 |
| Week 8 (Day 56) — Mild | 6 |
| Week 8 (Day 56) — Moderate | 3 |
| Week 8 (Day 56) — Severe | 0 |
| Week 8 (Day 56) — Very severe | 0 |
| End of Treatment (last value recorded) — Clear | 9 |
| End of Treatment (last value recorded) — Almost clear | 14 |
| End of Treatment (last value recorded) — Mild | 6 |
| End of Treatment (last value recorded) — Moderate | 3 |
| End of Treatment (last value recorded) — Severe | 1 |
| End of Treatment (last value recorded) — Very severe | 0 |
The assessment of the disease severity of the intertriginous areas was made using the 6-category scale; clear, almost clear, mild, moderate, severe, very severe. Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) Mild (Infiltration = slight, subtle thickening or infiltration, only marginally increased from normal skin, Erythema = light pink colour) Moderate (Infiltration = palpable thickening or infiltration without elevation, Erythema = definite pink colour) Severe (Infiltration = palpable thickening or infiltration with elevation, Erythema = very bright red coloration) Very severe (Infiltration = marked thickening or infiltration with rounded or sloped edges, Erythema = bright deep red coloration)
| Participants | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Baseline — Clear | 0 |
| Baseline — Almost clear | 0 |
| Baseline — Mild | 0 |
| Baseline — Moderate | 19 |
| Baseline — Severe | 12 |
| Baseline — Very severe | 2 |
| Week 2 (Day 14) — Clear | 0 |
| Week 2 (Day 14) — Almost clear | 7 |
| Week 2 (Day 14) — Mild | 16 |
| Week 2 (Day 14) — Moderate | 9 |
| Week 2 (Day 14) — Severe | 1 |
| Week 2 (Day 14) — Very severe | 0 |
| Week 4 (Day 28) — Clear | 5 |
| Week 4 (Day 28) — Almost clear | 15 |
| Week 4 (Day 28) — Mild | 10 |
| Week 4 (Day 28) — Moderate | 2 |
| Week 4 (Day 28) — Severe | 1 |
| Week 4 (Day 28) — Very severe | 0 |
| Week 6 (Day 42) — Clear | 4 |
| Week 6 (Day 42) — Almost clear | 17 |
| Week 6 (Day 42) — Mild | 5 |
| Week 6 (Day 42) — Moderate | 2 |
| Week 6 (Day 42) — Severe | 0 |
| Week 6 (Day 42) — Very severe | 0 |
| Week 8 (Day 56) — Clear | 7 |
| Week 8 (Day 56) — Almost clear | 12 |
| Week 8 (Day 56) — Mild | 7 |
| Week 8 (Day 56) — Moderate | 2 |
| Week 8 (Day 56) — Severe | 0 |
| Week 8 (Day 56) — Very severe | 0 |
| End of Treatment (last value recorded) — Clear | 10 |
| End of Treatment (last value recorded) — Almost clear | 13 |
| End of Treatment (last value recorded) — Mild | 7 |
| End of Treatment (last value recorded) — Moderate | 2 |
| End of Treatment (last value recorded) — Severe | 1 |
| End of Treatment (last value recorded) — Very severe | 0 |
Collected over From baseline visit (Day -7 to -3) to Follow-up 1 (end of treatment +14 ± 2) and Follow-up 2 (end of treatment +28 ± 2).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Calcipotriol Plus Hydrocortisone (LEO 80190) | 0/33 (0%) | 0/33 (0%) | 15/33 (45.5%) |
| Event | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| HeadacheNervous system disorders | 4/33 |
| NasopharyngitisInfections and infestations | 3/33 |
| NauseaGastrointestinal disorders | 2/33 |
| Back painMusculoskeletal and connective tissue disorders | 2/33 |
| LymphadenopathyBlood and lymphatic system disorders | 1/33 |
| Ear disorderEar and labyrinth disorders | 1/33 |
| Irritable bowel syndromeGastrointestinal disorders | 1/33 |
| Application site burningGeneral disorders | 1/33 |
| Application site pruritusGeneral disorders | 1/33 |
| BronchitisInfections and infestations | 1/33 |
| Age, Continuous(years) | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Mean | 47.4 ± 15.9 |
| Sex: Female, Male(Participants) | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Female | 14 |
| Male | 19 |
| Region of Enrollment(participants) | Calcipotriol Plus Hydrocortisone (LEO 80190) |
|---|---|
| Canada | 8 |
| United States | 7 |
| United Kingdom | 11 |
| Germany | 7 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of May 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2020, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Hydrocortisone